Similarly whole-grain intervention (12 weeks) in patients with NAFLD (n=112 randomly assigned into two groups), was associated with a significant reduction in NAFLD grade and ALT, AST and γ-glutamyltransferase levels independent of any changes in anthropometric measurements [110]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.